January 9, 2018 / 3:42 PM / 11 days ago

BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

Jan 9 (Reuters) - Inflarx Nv:

* INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA

* INFLARX NV - ‍INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below